AIM – A Decade of Achievement Hardman & Co Monthly

Hardman & Co

Hardman &Amp; Co Report Report DownloadsIn the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years.

► AIM, which was founded in 1995, now hosts 959 stocks, currently worth over £100 billion.

► Since its founding, over £100 billion has been raised by AIM-quoted stocks – with 2006 and 2007 being its best years.

► The AIM Index has risen by 31% over the last year and by over 60% during the last five years. Impressive.

► AIM now hosts eleven companies with valuations of over £1 billion each, led by top on-line clothing retailer ASOS, currently worth c£5 billion.

► Liquidity on AIM has improved remarkably in recent years – Read Keith Hiscock’s article: Liquidity – little understood, even before MIFID II.

Share on:

Latest Company News

Likewise expands distribution capacity to support its next growth phase

Likewise is expanding its Yorkshire and Newport distribution capacity as it builds the infrastructure needed to support its next stage of growth.

EDX Medical builds scale through Scottish Prostate Cancer Testing programme

EDX Medical is expanding its role in a 25,000-participant Scottish programme testing a more targeted approach to prostate cancer detection.

James Cropper reports stronger FY26 profit and reduced net debt

James Cropper delivered a 3.6% rise in revenue to £102.9m and increased adjusted EBITDA by 33% to £8.9m, supported by record Advanced Materials sales, improved Paper & Packaging performance and lower net debt.

Convatec names NED and outlines CFO transition

Convatec has outlined finance leadership changes, appointed Tobias Hestler as a Non-Executive Director and reaffirmed its 2026 expectations.

Rio Tinto maintains 2026 guidance as iron ore sales and lithium output rise

Rio Tinto reported higher first-half copper equivalent production, with stronger copper and lithium output and unchanged full-year guidance.

Cizzle Biotechnology reports US accreditation and patent progress in H1 2026

Cizzle Biotechnology entered its commercialisation phase during the first half of 2026 after securing CLIA accreditation for its CIZ1B early lung cancer test in the U.S. The company also strengthened its North American patent position and increased guaranteed minimum royalty receipts to approximately US$5.9 million.

    Search